Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

Inclusion Criteria: Histologically confirmed colorectal cancer Metastatic or unresectable disease OR diagnosis of solid tumor No known brain metastases ECOG 0-1 OR Karnofsky 70-100% Life expectancy > 12 weeks Absolute neutrophil count ≥ 1,500/mm^3 WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST and ALT ≤ 3 times upper limit of normal Creatinine normal OR creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study participation No ongoing or active infection No neuropathy > grade 1 No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs No psychiatric illness or social situation that would preclude study compliance No psychiatric illness or social situation that would preclude study compliance No other uncontrolled illness Prior bevacizumab and/or cetuximab allowed No concurrent routine or prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) More than 4 weeks since prior radiotherapy Recovered from prior therapy At least 2 weeks since prior valproic acid No concurrent combination anti-retroviral therapy for HIV-positive patients No other concurrent investigational agents No other concurrent anticancer therapy